What is Element Science?
Element Science is a pioneering med-tech enterprise dedicated to the development of the Jewel Patch, a wearable cardioverter defibrillator designed for continuous, non-invasive patient monitoring. By leveraging advanced sensor technology and machine learning, the company provides high-risk patients with a sophisticated, FDA-approved solution that offers protection outside of traditional clinical settings. Positioned at the intersection of digital health and cardiology, Element Science is actively disrupting the standard of care for cardiac rhythm management, aiming to improve patient outcomes through innovation and rigorous clinical validation.
How much funding has Element Science raised?
Element Science has raised a total of $263.4M across 4 funding rounds:
Series A
$12.5M
Private Equity
$25M
Series B
$80.3M
Series C
$145.6M
Series A (2014): $12.5M with participation from GV, Prospect Venture Partners, and Third Rock Ventures
Private Equity (2016): $25M, investors not publicly disclosed
Series B (2020): $80.3M supported by Foresite Capital, JS Capital LLC, Fidelity Management & Research Company, and Venrock
Series C (2020): $145.6M featuring Qiming Venture Partners USA, Invus Opportunities, Third Rock Ventures, Google Ventures, Deerfield Healthcare, and Cormorant Asset Management
Key Investors in Element Science
Third Rock Ventures
A healthcare venture firm focused on disruptive areas of science and medicine, dedicated to launching companies that make a dramatic difference in patient lives.
Google Ventures
A global venture capital firm that invests across multiple stages and sectors, including life sciences and frontier technology innovations.
Cormorant Asset Management
A prominent life sciences investment firm focused on fundamental scientific principles to support innovative private and public companies in the biotech sector.
What's next for Element Science?
With the successful completion of its latest financing round, Element Science is well-positioned to accelerate its commercialization efforts and expand its market reach. The company is expected to focus on scaling its manufacturing capabilities and deepening its clinical evidence base to support broader adoption of the Jewel Patch. As the firm transitions into a more mature operational phase, strategic priorities will likely include enhancing its data analytics infrastructure and strengthening its presence within the global cardiac health market, ensuring that its life-saving technology reaches a wider demographic of high-risk patients.
See full Element Science company page
